Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges

World J Gastroenterol. 2019 Jun 21;25(23):2839-2845. doi: 10.3748/wjg.v25.i23.2839.

Abstract

Pancreatic cancer is one of the leading causes of cancer death worldwide. Adjuvant chemotherapy has been developed based on the experiences made with palliative chemotherapy, and advocated to improve long-term survival of patients with this disease. However, the optimal chemotherapeutic regimen remains controversial. Recently, Conroy et al demonstrated the impressive benefits of modified FOLFIRINOX over gemcitabine alone in the multicenter Partenariat de Recherche en Oncologie Digestive 24 (PRODIGE-24) trial. The remarkable results mark a new milestone in treating resectable pancreatic cancer and have now changed the standard of care for this patient population. In this commentary, we discuss an issue of difference of tumor grade between the PRODIGE-24 trial and previous phase III trials. We also discuss potential biomarkers predicting therapeutic response to modified FOLFIRINOX. Finally, we summarize several ongoing clinical trials of replacing part of the FOLFIRINOX regimen with Xeloda/S-1/nanoliposomal irinotecan for pancreatic cancer.

Keywords: Adjuvant therapy; FOLFIRINOX; Nanoliposomal irinotecan; Neutrophil-to-lymphocyte; Pancreatic cancer.

Publication types

  • Review
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols*
  • Deoxycytidine / analogs & derivatives
  • Fluorouracil
  • Gemcitabine
  • Germany
  • Humans
  • Irinotecan
  • Leucovorin
  • Pancreatic Neoplasms*

Substances

  • Deoxycytidine
  • Irinotecan
  • Leucovorin
  • Fluorouracil
  • Gemcitabine